Mode
Text Size
Log in / Sign up

Host factors influence viral entry and replication in HPIV infected infants, elderly, and immunocompromised individualsHost factors influence how the parainfluenza virus infects vulnerable people

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider host-directed therapies for human parainfluenza virus infections in vulnerable populations.

This narrative review examines host factors influencing viral entry, replication, assembly, release, and innate immunity evasion in human parainfluenza virus infected individuals. The scope of the discussion includes infants, the elderly, immunocompromised individuals, and children under five. The review does not report a specific sample size or setting. The authors focus on the biological mechanisms rather than clinical trial data or adverse events. The publication type is a review, not a primary study. The authors do not provide specific outcome data or p-values. The review aims to accelerate the development of innovative host-directed therapies. This approach targets the underlying biological processes of the virus. The text does not make causal claims about specific interventions. The limitations of the review are not explicitly detailed in the provided text. The practice relevance is to accelerate the development of innovative host-directed therapies. The review avoids overstatement of certainty regarding the efficacy of these therapies.

This narrative review looks at human parainfluenza virus infections in specific groups. The focus is on infants, the elderly, immunocompromised individuals, and children under five. The authors examine host factors that influence viral entry, replication, assembly, release, and innate immunity evasion. This review aims to accelerate the development of innovative host-directed therapies for these conditions.

The study does not report a specific sample size or follow-up period. It is a narrative review, which means it summarizes existing knowledge rather than presenting new clinical trial data. No specific medications were tested in this analysis.

Safety concerns were not reported in this review. The main reason to be careful is that this is a narrative review, not a clinical trial. Readers should understand that this information helps guide future research into host-directed therapies rather than providing immediate treatment options for acute respiratory infections.

What this means for you:
This review discusses host factors in parainfluenza infections to help develop new therapies.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Human parainfluenza viruses (HPIVs)are significant pathogens responsible for acute respiratory infections in infants, the elderly, and immunocompromised individuals. Among children under five, HPIVs are the second most common viral cause of acute lower respiratory tract infections (ALRIs), surpassed only by respiratory syncytial virus (RSV). Despite their significant health impact, there are currently no licensed vaccines or specific antiviral treatments for HPIV infection. Recent advances in functional genomics, including CRISPR-Cas9 screening, cDNA library screening, and multi-omics approaches, have enabled the systematic identification of host factors essential at different stages of HPIVs infections. This review aims to systematically summarize the latest evidence on host factors that influence viral entry, replication, assembly, and release, as well as those involved in evasion of innate immunity. Importantly, we contextualize the mechanisms of these host factors within the broader network of virus-host interactions. By integrating these insights, we aim to provide a strong mechanistic foundation for understanding HPIV pathogenesis to accelerate the development of innovative host-directed therapies(HDTs).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.